• +1-646-491-9876
    • +91-20-67278686

    Search

    Meningitis Pipeline Review H1 2017

    Meningitis Pipeline Review H1 2017

    • Report Code ID: RW0001858656
    • Category Pharmaceuticals
    • No. of Pages 54
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Meningitis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2017, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

    Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ( (inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light) , phonophobia (fear of loud noises) . In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby's head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

    Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Meningitis - Overview
    Meningitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Meningitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Meningitis - Companies Involved in Therapeutics Development
    Chongqing Zhifei Biological Products Co Ltd
    ContraFect Corp
    Matinas BioPharma Holdings Inc
    Viamet Pharmaceuticals Inc
    Meningitis - Drug Profiles
    (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-302 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-303 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-309 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EUC-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    meningitis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    meningococcal [serotypes A, C] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pneumococcal [serotype 4, 6A] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Neuraminidase A for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target PknD for Tuberculous Meningitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VT-1129 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VY-OZ - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Meningitis - Dormant Projects
    Meningitis - Discontinued Products
    Meningitis - Product Development Milestones
    Featured News & Press Releases
    Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
    May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM Microbe 2017 Conference
    Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated
    Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis
    Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis
    Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine
    Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015
    Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Meningitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2017
    Meningitis - Pipeline by ContraFect Corp, H1 2017
    Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
    Meningitis - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
    Meningitis - Dormant Projects, H1 2017
    Meningitis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Meningitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Chongqing Zhifei Biological Products Co Ltd
    ContraFect Corp
    Matinas BioPharma Holdings Inc
    Viamet Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//meningitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//meningitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//meningitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments